Interleukin-5 and eosinphils as therapeutic targets for asthma
Extensive clinical investigations have implicated eosinophils in the pathogenesis of asthma. In a recent clinical trial, humanized monoclonal antibody to interleukin (IL)-5 significantly limited eosinophil migration to the lung. However, treatment did not affect the development of the late-phase response or airways hyperresponsiveness in experimental asthma. Although IL-5 is a key regulator of eosinophilia and attenuation of its actions without signs of clinical improvement raises questions...[Show more]
|Collections||ANU Research Publications|
|Source:||Trends in Molecular Medicine|
|01_Foster_Interleukin-5_and_eosinphils_2002.pdf||272.2 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.